Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia.
Selectins mediate the adhesion of leukocytes to activated endothelial cells and activated platelets. In addition to these cell-to-cell interactions, they influence the fibrin content and size of venous thrombi in different animal models. However, the exact role of selectins in human endotoxemia still remains unclear. We aimed to investigate the effect of selectin inhibition in lipopolysaccharide (LPS)-induced tissue factor (TF)-dependent activation of coagulation in a well-standardized model of human endotoxemia. To explore whether selectin blockade attenuates LPS-induced coagulation in humans, we performed a randomized, double-bind placebo-controlled crossover trial in 16 healthy male volunteers. All subjects received 2 ng/kg of LPS and, 10 min thereafter, a 15-min infusion of either 30 mg/kg of the pan-selectin antagonist bimosiamose or equal volumes of placebo in random order, with a washout period of 6 weeks between both periods. Treatment with bimosiamose had no significant effect on LPS-induced TF expression, as quantified by TF mRNA levels, or on LPS-induced coagulation response, reflected by increases in plasma thrombin-antithrombin (TAT) complexes and prothrombin fragment (F1 + 2) levels. Furthermore, bimosiamose did not affect the LPS-dependent changes in leukocyte subpopulations or the increase in platelet-leukocyte aggregates, as determined in the level of CD41+ monocytes. Finally, neither the LPS-induced release of tumor necrosis factor, interleukin 6, leukocyte expression of CD11b, nor intercellular adhesion molecule 1 were affected by administration of bimosiamose. The pan-selectin antagonist bimosiamose does not attenuate TF-triggered coagulation or inflammation in human endotoxemia. This indicates a minor influence of this selectin antagonist in this model. In addition, infusion of bimosiamose was safe and well tolerated in human endotoxemia.
Mayr
Florian B
FB
Department of Clinical Pharmacology, Medical University of Vienna, Austria.
Firbas
Christa
C
Leitner
Judith M
JM
Spiel
Alexander O
AO
Reiter
Rosemarie A
RA
Beyer
Diana
D
Meyer
Michael
M
Wolff
Gerhard
G
Jilma
Bernd
B
D000293:Adolescent; D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D018592:Cross-Over Studies; D004311:Double-Blind Method; D019446:Endotoxemia / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D005434:Flow Cytometry; D006439:Hemodynamics / Q000187:drug effects; D006586:Hexanes / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007962:Leukocytes / Q000187:drug effects / Q000378:metabolism; D008070:Lipopolysaccharides; D008297:Male; D008358:Mannose / Q000031:analogs & derivatives* / Q000494:pharmacology; D040201:Platelet Membrane Glycoprotein IIb / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019087:Selectins / Q000378:metabolism*; D013925:Thromboplastin / Q000235:genetics; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D015815:Cell Adhesion Molecules; D006586:Hexanes; D015850:Interleukin-6; D008070:Lipopolysaccharides; D040201:Platelet Membrane Glycoprotein IIb; D012333:RNA, Messenger; D019087:Selectins; D014409:Tumor Necrosis Factor-alpha; D013925:Thromboplastin; C496819:bimosiamose; D008358:Mannose